Crossover Analysis from the PLUDO PR21 Trial of Lutetium-177 vs. Docetaxel - Kim Chi
Kim Chi
Kim Chi presents PLUDO crossover analyses, building on the primary PR21 results showing no rPFS difference but an overall survival advantage for the docetaxel-first arm versus lutetium-first in ARPI-pretreated mCRPC.